< 生产厂家价格 >

盐酸替罗非班

盐酸替罗非班用途

Tirofiban盐酸盐一水合物是非肽类,糖蛋白IIb/IIIa拮抗剂。

点击显示

盐酸替罗非班名称

[ CAS 号 ]:
150915-40-5

[ 中文名 ]:
盐酸替罗非班

[ 英文名 ]:
Tirofiban hydrochloride

[中文别名 ]:

[英文别名 ]:

Tirofiban hydrochloride
Tirofiban hydrochloride monohydrate
tirofiban hydrochloride anhydrous
Tirofiban Hydrochloride Hydrate
Tirofiban (hydrochloride monohydrate)

盐酸替罗非班生物活性

[ 描述 ]:

Tirofiban盐酸盐一水合物是非肽类,糖蛋白IIb/IIIa拮抗剂。

[ 相关类别 ]:

信号通路 >> 细胞骨架 >> Integrin

研究领域 >> 心血管疾病

[参考文献]

[1]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46.

[2]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100.

[3]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49.

[4]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19.

[5]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.

[相关活性小分子]

盐酸替罗非班物理化学性质

[ 沸点 ]:
611.7ºC at 760 mmHg

[ 熔点 ]:
135-137ºC

[ 分子式 ]:
C₂₂H₃₉ClN₂O₆S

[ 分子量 ]:
495.073

[ 闪点 ]:
323.7ºC

[ 精确质量 ]:
494.221741

[ PSA ]:
122.34000

[ LogP ]:
5.48870

[ 外观性状 ]:
白色固体

[ 储存条件 ]:
-20°C Freezer

[ 水溶解性 ]:
DMSO: >12mg/mL at warmed to 60°C

盐酸替罗非班安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H315-H319-H335

[ 警示性声明 ]:
P261-P305 + P351 + P338

[ 危害码 (欧洲) ]:
Xi

[ 风险声明 (欧洲) ]:
36/37/38

[ 安全声明 (欧洲) ]:
26-37-45

[ 危险品运输编码 ]:
NONH for all modes of transport

盐酸替罗非班文献

Influence of Body Mass Index on the Activated Clotting Time Under Weight-Based Heparin Dose.

J. Clin. Lab Anal. 30 , 108-13, (2016)

Activated clotting time (ACT) has been successfully applied during percutaneous coronary intervention (PCI) to monitor the extent of thrombin inhibition and anti-coagulation from unfractionated hepari...

更多文献